Micromet to Report Blinatumomab Data at 2011 American Society of Hematology Annual Meeting

–Updated results from Phase 2 blinatumomab ALL trial accepted for oral presentation–

ROCKVILLE, Md.--(BUSINESS WIRE)-- Micromet, Inc. (NASDAQ: MITI), a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced that data on its lead product candidate blinatumomab (MT103) will be reported at the 53rd Annual American Society of Hematology (ASH) Annual Meeting, to be held December 10 – 13 in San Diego, California.

Accepted abstracts include:

Abstract #: 252
Abstract title: Anti-CD19 BiTE Blinatumomab Induces High Complete Remission Rate In Adult Patients with Relapsed B-Precursor ALL: Updated Results of An Ongoing Phase II Trial
First author: Max Topp, MD, University of Wuerzburg, Wuerzburg, Germany
Presentation date and time: Monday, December 12, 8:15 AM ET
Location: San Diego Convention Center, Room 29

Abstract #: 1637
Abstract title: Blinatumomab Monotherapy Shows Efficacy in Patients with Relapsed Diffuse Large B Cell Lymphoma
First author: Andreas Viardot, MD, University Hospital Ulm, Ulm, Germany
Presentation date and time: Saturday, December 10, 5:30 PM - 7:30 PM
Location: San Diego Convention Center, Hall GH

Abstracts can be found at www.hematology.org.

About Blinatumomab

Blinatumomab (MT103) is a next-generation monoclonal antibody designed to direct the body's cell destroying T-cells against CD19, a protein expressed on the surface of B-cell derived acute lymphoblastic leukemias and non-Hodgkin's lymphomas.

Micromet has received orphan drug designation from the European Medicines Agency for blinatumomab for the treatment of acute lymphoblastic leukemia, mantle cell lymphoma and chronic lymphatic leukemia and from the U.S. Food and Drug Administration for the treatment of acute lymphoblastic leukemia, chronic lymphocytic leukemia and indolent B cell lymphoma.

About Micromet, Inc.

Micromet is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibody-based therapies for the treatment of cancer. The Company is advancing a robust pipeline of novel therapeutics based on its proprietary BiTE® technology. The Company's lead product candidate blinatumomab (MT103) is currently the subject of a European pivotal trial in patients with minimal residual disease positive acute lymphoblastic leukemia. Micromet has collaborations with a number of leading pharmaceutical and biotechnology companies, including Amgen, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim, MedImmune, Nycomed and Sanofi.


Micromet, Inc.
Jennifer Neiman
Director, Corporate Communications

KEYWORDS:   United States  North America  California

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Oncology  Pharmaceutical  Research  Science